Archives
-
Entinostat, HDAC1, and Axolotl Limb Regeneration
2026-10-16
Wang et al. reported that nerve-associated HDAC1 expression accompanied blastema formation and that pharmacological inhibition of class I HDAC activity delayed or impaired axolotl limb regeneration. The study provides convergent anatomical, molecular, pharmacological, and denervation evidence for an important role of HDAC activity, while stopping short of proving that HDAC1 alone is the direct causal effector or that findings transfer to oncology or human regeneration.
-
Entinostat and Nerve-Dependent Axolotl Regeneration
2026-10-16
Wang et al. reported that nerve-associated HDAC1 expression was temporally and spatially linked to axolotl limb regeneration, while pharmacological HDAC inhibition delayed regeneration and impaired blastema formation. The evidence supports a role for HDAC-sensitive activity in regeneration, but does not establish HDAC1 as the sole molecular target or prove that a commercial Entinostat formulation was used. Denervation, inhibitor selectivity, incomplete pharmacodynamic suppression, and species-specific biology limit extrapolation to cancer research or human tissue regeneration.
-
NAD+: Identity, Mechanism, and Evidence Boundaries
2026-10-15
A source-grounded overview of APExBIO’s NAD+ product description, covering molecular identity, redox and enzyme-related mechanisms, interpretation of NAD+ measurements, reported physicochemical properties, and the limits of the available evidence.
-
Medroxyprogesterone Acetate: Evidence and Scope
2026-10-15
Medroxyprogesterone acetate (MPA) is described by APExBIO as a synthetic steroidal progestin whose principal activity involves progesterone-receptor signaling, with additional receptor-independent effects linked in the product description to glucocorticoid-receptor binding. The same source reports renal epithelial gene-expression findings and neurobehavioral observations in aged ovariectomized rats, but provides no identity-matched paper, study-level statistics, or methodological detail. These claims therefore support a documented product and mechanism overview, not an independent assessment of efficacy, causality, or clinical applicability.
-
NAD+ and Cellular Stress: What the Evidence Shows
2026-10-14
The supplied breast-cancer study provides evidence about caspase-dependent stress adaptation, not about NAD+ itself. This overview separates the biochemical context of NAD+ from the study’s actual findings and outlines the evidence quality, uncertainties and limits on applying the results to other cells or to human treatment.
-
QPRT, P2Y11 Signaling, and Breast Cancer Invasion
2026-10-13
A 2021 study linked elevated QPRT with breast cancer invasiveness and reported that pharmacologic disruption of P2Y11-associated signaling reduced QPRT-related myosin light-chain phosphorylation and invasive behavior. The evidence supports a mechanistic association, but does not establish that P2Y11 is the sole or clinically validated mediator.
-
Entinostat and HDAC Signaling in Regeneration
2026-10-13
Entinostat, also known as MS-275, is a class I HDAC inhibitor studied in oncology and developmental biology. A 2019 axolotl study linked nerve-dependent HDAC1 expression with blastema formation and limb regeneration, while pharmacologic HDAC inhibition delayed or impaired regeneration. These findings support a role for HDAC activity in axolotl regeneration but do not establish that Entinostat can promote human tissue regeneration or predict cancer treatment outcomes.
-
SIRT1, Bone–Vascular Coupling, and Aging
2026-10-12
A preclinical study links reduced SIRT1 activity with impaired vascular and osteogenic function in aging bone, while identifying β-catenin/Wnt signaling as a possible mediator. The findings support a mechanistic hypothesis for skeletal regeneration but do not establish human efficacy, safety, or the use of any specific commercial product.
-
M344: Evidence, Context, and Key Limitations
2026-10-12
M344 is described by APExBIO as a cell-permeable histone deacetylase inhibitor with reported activity across several cellular and ex vivo research models. The available supplied evidence is primarily a product description rather than a fully documented primary study, while the cited degarelix article is unrelated and cannot substantiate claims about M344. Accordingly, reported effects should be treated as preliminary, model-specific observations rather than evidence of clinical efficacy.
-
ERK5, ERK1/2, and Vitamin D–Driven AML Differentiation
2026-10-10
Wang et al. distinguish the roles of ERK5 and ERK1/2 signaling in 1α,25-dihydroxyvitamin D3-induced differentiation of acute myeloid leukemia cells. Their findings connect ERK5 inhibition with altered myeloid marker expression and cell-cycle arrest, while showing that MEK1/2 inhibition produces a broader suppression of differentiation markers.
-
UBE2F–SAG Neddylation Activates RHEB in Liver Tumors
2026-10-09
Zhang and colleagues identify RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and connect modification at K169 with enhanced mTORC1 signaling. Cell, liver-model, and patient-association data suggest that this pathway contributes to steatosis and hepatocellular carcinoma, while also defining important boundaries for translation beyond the studied models.
-
Tunable Human Intestinal Organoids: Study Insights
2026-10-09
Yang et al. developed a human small intestinal organoid system designed to maintain high proliferation while expanding epithelial cell diversity. The study shows that coordinated small-molecule modulation can shift the balance between self-renewal and differentiation without recreating artificial spatial or temporal signaling gradients.
-
Apigenin Research: Oncology and Neuroprotection
2026-10-08
Apigenin, also known as 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one, is being investigated across oncology and neurodegeneration research. Supplied evidence includes a 2025 network-medicine study that identified apigenin as a leading flavonoid candidate in cellular Alzheimer’s disease models, alongside a supplier summary of malignant mesothelioma findings. This overview separates published observations from interpretation, compares evidence strength, and explains why cellular pathway results should not be treated as proof of clinical efficacy.
-
Tubastatin A in Post-Resuscitation Myocardial Injury
2026-10-08
A 2025 porcine study links Tubastatin A treatment with less myocardial dysfunction and injury after cardiac arrest and resuscitation. The findings suggest that HDAC6 inhibition may influence both GSDME-associated pyroptosis and MLKL-associated necroptosis, although the evidence remains mechanistic and preclinical rather than proof of a causal therapeutic pathway.
-
NADH as a Redox Lens for Bone Biology
2026-10-07
NADH is more than an energy-metabolism coenzyme: it can serve as a conceptual lens for interpreting redox-sensitive signaling in bone remodeling. This article connects reduced nicotinamide adenine dinucleotide research with catalpol-driven osteoclast apoptosis while separating direct evidence from testable hypotheses.